23 Sep 2005 - elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company.
Taapken (40), previously spent 3 years as a Partner in the life science team of DVC, Deutsche Venture Capital, and was a member of the supervisory board of elbion AG. He has resigned from DVC, and has also stepped down from his position as a supervisory board member of the company, to join elbion's management board. Prior to his position at DVC, Thomas Taapken worked for 8 years at Sanofi-Aventis in the areas of research, corporate development and venture capital. In his last position he held responsibility for the corporate venture capital activities of the group. Dr. Taapken holds a PhD in chemistry from the Technical University of Berlin.
 |
www.bionity.com/news/e/49107 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/49107 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |